FDA says Tysabri review a high priority
Fri, 24 Mar 2006 09:12 PM EST
... WASHINGTON (Reuters) - A review of Biogen Idec and Elan''s bid to return multiple sclerosis drug Tysabri to the market "continues to be a high priority," the Food and Drug Administration said on Friday. ...

Not Signed In -


